|
ES2582603T5
(es)
*
|
2008-10-01 |
2022-12-02 |
Amgen Res Munich Gmbh |
Anticuerpos biespecíficos de cadena sencilla con especificidad por antígenos diana de alto peso molecular
|
|
SMT201800109T1
(it)
*
|
2011-09-19 |
2018-05-02 |
Axon Neuroscience Se |
Terapia a base di proteine e diagnosi di una patologia mediata da tau nella malattia di alzheimer
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
|
WO2014059442A2
(en)
*
|
2012-10-12 |
2014-04-17 |
Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Antibody based reagents that specifically recognize toxic oligomeric forms of tau
|
|
EP2970453B1
(en)
|
2013-03-13 |
2019-12-04 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
LT3083680T
(lt)
*
|
2013-12-20 |
2020-04-10 |
F. Hoffmann-La Roche Ag |
Humanizuoti anti-tau(ps422) antikūnai ir jų naudojimo būdai
|
|
EP3083696B1
(en)
*
|
2013-12-20 |
2018-02-14 |
F.Hoffmann-La Roche Ag |
Bispecific her2 antibodies and methods of use
|
|
EP3696193A1
(en)
*
|
2014-02-02 |
2020-08-19 |
MedImmune Limited |
Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
|
|
WO2016050822A2
(en)
*
|
2014-09-30 |
2016-04-07 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (dprs) antibody
|
|
KR102689285B1
(ko)
|
2014-11-26 |
2024-07-31 |
젠코어 인코포레이티드 |
Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
|
|
JP6793134B2
(ja)
|
2015-06-05 |
2020-12-02 |
ジェネンテック， インコーポレイテッド |
抗ｔａｕ抗体及び使用方法
|
|
AR105089A1
(es)
|
2015-06-24 |
2017-09-06 |
Hoffmann La Roche |
ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
|
|
MY187033A
(en)
*
|
2015-06-24 |
2021-08-27 |
Japan Chem Res |
Anti-human transferrin receptor antibody permeating blood-brain barrier
|
|
CA2990565A1
(en)
|
2015-06-24 |
2016-12-29 |
Jcr Pharmaceuticals Co., Ltd. |
Fusion protein containing bdnf and anti-human transferrin receptor antibody
|
|
MA42377A
(fr)
|
2015-07-06 |
2018-05-16 |
Ucb Biopharma Sprl |
Anticorps se liant à tau
|
|
US10344081B2
(en)
|
2015-07-06 |
2019-07-09 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
CN108137679B
(zh)
*
|
2015-08-13 |
2022-07-19 |
纽约大学 |
对Tau的{p}Ser404表位有选择性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
|
|
US10766954B2
(en)
*
|
2016-04-06 |
2020-09-08 |
Imago Pharmaceuticals, Inc. |
Therapeutic antibodies for treatment of neurodegeneration
|
|
SG11201808434WA
(en)
*
|
2016-05-02 |
2018-10-30 |
Prothena Biosciences Ltd |
Antibodies recognizing tau
|
|
PT3452507T
(pt)
|
2016-05-02 |
2022-12-20 |
Prothena Biosciences Ltd |
Imunoterapia anti-tau
|
|
US10906964B2
(en)
|
2016-05-02 |
2021-02-02 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
WO2017220555A1
(en)
|
2016-06-20 |
2017-12-28 |
F-Star Beta Limited |
Lag -3 binding members
|
|
WO2018017370A1
(en)
*
|
2016-07-20 |
2018-01-25 |
Anahit Ghochikyan |
Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
|
|
WO2018018031A1
(en)
*
|
2016-07-22 |
2018-01-25 |
New York University |
Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides
|
|
CN110248959B
(zh)
|
2016-12-07 |
2023-06-30 |
基因泰克公司 |
抗tau抗体和使用方法
|
|
MY198942A
(en)
|
2016-12-07 |
2023-10-03 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
|
CN110366564B
(zh)
*
|
2016-12-23 |
2023-07-07 |
瑞美德生物医药科技有限公司 |
使用与程序性死亡1(pd-1)结合的抗体的免疫疗法
|
|
KR102466248B1
(ko)
|
2016-12-26 |
2022-11-10 |
제이씨알 파마 가부시키가이샤 |
혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
|
|
CN110100000B
(zh)
|
2016-12-26 |
2023-06-20 |
Jcr制药股份有限公司 |
含有bdnf的融合蛋白
|
|
CN110494445B
(zh)
*
|
2017-01-06 |
2023-10-20 |
Abl生物公司 |
抗α-SYN抗体及其用途
|
|
KR102613874B1
(ko)
*
|
2017-01-30 |
2023-12-15 |
알렉시온 파마슈티칼스, 인코포레이티드 |
1가 항-프로페르딘 항체 및 항체 단편
|
|
EP3580241A4
(en)
*
|
2017-02-10 |
2021-01-06 |
The Trustees Of The University Of Pennsylvania |
ANTI-FACTOR D ANTIBODIES AND USES OF THESE LATEST
|
|
CA3055541A1
(en)
*
|
2017-03-06 |
2018-09-13 |
The Trustees Of The University Of Pennsylvania |
Anti-c5 antibodies and uses thereof
|
|
JP7251792B2
(ja)
*
|
2017-03-23 |
2023-04-04 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
抗Ｃ５ａ抗体とその使用
|
|
CN110382542B
(zh)
*
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
|
CN110691793A
(zh)
*
|
2017-04-26 |
2020-01-14 |
田边三菱制药株式会社 |
黏结蛋白聚糖-1（cd138）结合剂及其用
|
|
CN110881274B
(zh)
|
2017-05-02 |
2024-11-15 |
普罗塞纳生物科学有限公司 |
识别tau的抗体
|
|
EP3634987A4
(en)
*
|
2017-05-30 |
2021-03-03 |
The University of British Columbia |
EPITOPES IN RNA RECOGNITION MOTIVE 1 (RRM1) OF TDP-43 AND MISFOLDING-SELECTIVE ANTIBODIES
|
|
EP3431496A1
(en)
*
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti- isoasp7 amyloid beta antibodies and uses thereof
|
|
JP7368856B2
(ja)
|
2017-07-25 |
2023-10-25 |
トゥルーバインディング，インコーポレイテッド |
Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
|
|
AU2018312441B2
(en)
*
|
2017-08-02 |
2024-10-17 |
Stressmarq Biosciences Inc. |
Antibody binding active alpha-synuclein
|
|
CA3115374A1
(en)
*
|
2017-10-12 |
2019-04-18 |
Keio University |
Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
|
|
CN112040970A
(zh)
*
|
2017-11-29 |
2020-12-04 |
得克萨斯大学体系董事会 |
用于癌症疗法的组合物和方法
|
|
RU2020118519A
(ru)
*
|
2017-12-05 |
2022-01-10 |
Мабион Са |
Комбинированная терапия рассеянного склероза, включающая лиганд CD20
|
|
CN116731173A
(zh)
|
2017-12-14 |
2023-09-12 |
Abl生物公司 |
抗a-syn/igf1r的双特异性抗体及其用途
|
|
WO2019118906A2
(en)
*
|
2017-12-14 |
2019-06-20 |
University Of Florida Research Foundation |
Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein
|
|
EP3724232B1
(en)
|
2017-12-14 |
2024-12-04 |
The University of Ottawa |
Exosome packaging and targeted autophagy
|
|
CA3085785A1
(en)
*
|
2017-12-19 |
2019-06-27 |
Surrozen, Inc. |
Anti-lrp5/6 antibodies and methods of use
|
|
AU2018393073B2
(en)
|
2017-12-19 |
2025-09-18 |
Surrozen Operating, Inc. |
Wnt surrogate molecules and uses thereof
|
|
WO2019133512A1
(en)
*
|
2017-12-29 |
2019-07-04 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
|
CN111886247A
(zh)
*
|
2018-01-05 |
2020-11-03 |
Ac免疫有限公司 |
错折叠tdp-43结合分子
|
|
SG11202006770PA
(en)
*
|
2018-01-29 |
2020-08-28 |
Univ California |
Therapies and methods to treat tlr2-mediated diseases and disorders
|
|
CN111971301B
(zh)
|
2018-01-31 |
2025-01-07 |
艾莱克特有限责任公司 |
抗ms4a4a抗体及其使用方法
|
|
CN112204050B
(zh)
|
2018-01-31 |
2025-03-14 |
艾莱克特有限责任公司 |
抗ms4a6a抗体及其使用方法
|
|
AU2019215202B2
(en)
*
|
2018-02-01 |
2025-11-13 |
Memorial Sloan Kettering Cancer Center |
Antibodies to Galectin-3 and methods of use thereof
|
|
US12398201B2
(en)
*
|
2018-02-19 |
2025-08-26 |
New York University |
Tau single domain antibodies
|
|
AU2019226101A1
(en)
|
2018-02-23 |
2020-09-17 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
CD83-binding chimeric antigen receptors
|
|
IL277215B2
(en)
|
2018-03-14 |
2025-10-01 |
Boehringer Ingelheim Int |
Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis
|
|
BR112020018755A2
(pt)
*
|
2018-03-20 |
2021-01-05 |
Novartis Ag |
Combinações farmacêuticas
|
|
AU2018418224B2
(en)
*
|
2018-04-09 |
2025-04-17 |
Oricell Therapeutics Co., Ltd. |
Anti-PD-L1 antibody and use thereof
|
|
JP2021520854A
(ja)
*
|
2018-04-11 |
2021-08-26 |
タイチャン ピーティーイー．リミテッドＴｙｃｈａｎ Ｐｔｅ．Ｌｔｄ． |
黄熱を処置するための方法および組成物
|
|
WO2019197651A1
(en)
*
|
2018-04-12 |
2019-10-17 |
Mediapharma S.R.L. |
Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
|
|
AU2019259798A1
(en)
*
|
2018-04-24 |
2020-11-12 |
Neuracle Science Co., Ltd. |
Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain
|
|
BR112020020390A2
(pt)
*
|
2018-04-25 |
2021-01-19 |
Medimmune Limited |
Formulações de anticorpos anti-pd-l1 humanos
|
|
GB201806918D0
(en)
*
|
2018-04-27 |
2018-06-13 |
Enleofen Bio Pte Ltd |
Combination treatment for eye fibrosis
|
|
JP2021521896A
(ja)
|
2018-04-27 |
2021-08-30 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
ヒト由来の抗（ポリｇａ）ジペプチドリピート（ｄｐｒ）抗体
|
|
WO2019224724A1
(en)
*
|
2018-05-23 |
2019-11-28 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmaceutical compositions comprising antibody variants
|
|
WO2019225787A1
(ko)
*
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
CN112204049B
(zh)
*
|
2018-05-29 |
2025-04-18 |
芬兰国家技术研究中心股份公司 |
抗甲状腺激素(t4)重组抗体或抗原结合片段
|
|
WO2019229155A1
(en)
*
|
2018-05-31 |
2019-12-05 |
Glenmark Pharmceuticals S.A. |
Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
|
|
CN110577597B
(zh)
*
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技（成都）有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
|
WO2019241707A1
(en)
*
|
2018-06-14 |
2019-12-19 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for preventing or reversing t-cell exhaustion through ectonucleotidase inhibition antibody-mediated target cytosis
|
|
JP7513533B2
(ja)
*
|
2018-07-02 |
2024-07-09 |
アブセントラ，エルエルシー |
リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
CA3106046A1
(en)
|
2018-07-12 |
2020-01-16 |
F-Star Beta Limited |
Antibody molecules that bind pd-l1 and cd137
|
|
ES3044118T3
(en)
*
|
2018-07-12 |
2025-11-26 |
Invox Pharma Ltd |
Antibody molecules that bind cd137 and ox40
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
CN110713537B
(zh)
*
|
2018-07-13 |
2023-04-21 |
江苏怀瑜药业有限公司 |
一种sema4d抗体及其制备方法和应用
|
|
CN112513078B
(zh)
*
|
2018-07-31 |
2022-11-18 |
沈为群 |
抗il-17a抗体及其用途
|
|
CA3108795A1
(en)
*
|
2018-08-08 |
2020-02-13 |
Orionis Biosciences, Inc. |
Sirp1a targeted chimeric proteins and uses thereof
|
|
EP3833693A4
(en)
*
|
2018-08-21 |
2023-06-07 |
ABL Bio Inc. |
Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
|
|
CN113038967A
(zh)
|
2018-09-06 |
2021-06-25 |
宾夕法尼亚大学理事会 |
人源化抗c5抗体及其用途
|
|
CN111253485A
(zh)
*
|
2018-11-30 |
2020-06-09 |
上海开拓者生物医药有限公司 |
抗人tim-3单克隆抗体及其应用
|
|
MY206649A
(en)
*
|
2018-11-30 |
2024-12-30 |
I Mab Biopharma Us Ltd |
Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
|
|
JP6892180B2
(ja)
*
|
2018-12-03 |
2021-06-23 |
株式会社ｍＡｂＰｒｏｔｅｉｎ |
活性型インターロイキン−１８タンパク質のネオエピトープを認識する抗体、及びその応用
|
|
EP3893901A4
(en)
*
|
2018-12-11 |
2023-01-04 |
The Regents of the University of California |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES
|
|
TWI734279B
(zh)
*
|
2018-12-14 |
2021-07-21 |
美商美國禮來大藥廠 |
抗α-突觸核蛋白抗體及其用途
|
|
CN116063505B
(zh)
|
2019-01-30 |
2024-05-03 |
真和制药有限公司 |
抗gal3抗体及其用途
|
|
AU2020223293A1
(en)
*
|
2019-02-15 |
2021-08-19 |
Integral Molecular, Inc. |
Claudin 6 antibodies and uses thereof
|
|
JP2022520632A
(ja)
|
2019-02-15 |
2022-03-31 |
インテグラル・モレキュラー・インコーポレイテッド |
共通軽鎖を含む抗体及びその使用
|
|
KR20210118945A
(ko)
*
|
2019-02-15 |
2021-10-01 |
유니버시티 오브 써던 캘리포니아 |
Lym-1 및 lym-2 항체 조성물 및 개선된 car 구성물
|
|
CA3131531A1
(en)
|
2019-03-03 |
2020-09-10 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
EP3947445A1
(en)
*
|
2019-04-04 |
2022-02-09 |
Vanderbilt University |
Hiv/hcv cross-reactive antibodies and uses thereof
|
|
TW202106711A
(zh)
*
|
2019-04-24 |
2021-02-16 |
美商健生生物科技公司 |
抗體調配物
|
|
EP3966240A1
(en)
*
|
2019-05-08 |
2022-03-16 |
Novartis AG |
Anti-cd40 antibodies for use in treatment of t1dm and insulitis
|
|
CA3138414A1
(en)
*
|
2019-05-16 |
2020-11-19 |
Qilu Pharmaceutical Co., Ltd. |
Antibodyagainst claudin 18a2 and use thereof
|
|
TW202110878A
(zh)
*
|
2019-05-16 |
2021-03-16 |
法商賽諾菲公司 |
在神經系統中表現抗原結合蛋白
|
|
TWI844684B
(zh)
*
|
2019-06-04 |
2024-06-11 |
大陸商普米斯生物技術（珠海）有限公司 |
一種抗ceacam5的單殖株抗體及其製備方法和用途
|
|
JP7617040B2
(ja)
*
|
2019-06-13 |
2025-01-17 |
プレステージ バイオファーマ リミテッド |
Ｃｔｈｒｃ１に特異的な新規抗体及びその使用
|
|
FR3099160B1
(fr)
*
|
2019-07-23 |
2022-05-06 |
Univ Grenoble Alpes |
Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
|
|
CN114286827B
(zh)
*
|
2019-07-26 |
2024-01-12 |
神州细胞工程有限公司 |
人源化抗il17a抗体及其应用
|
|
MY208743A
(en)
*
|
2019-07-31 |
2025-05-27 |
Alector Llc |
Anti-ms4a4a antibodies and methods of use thereof
|
|
EP4013515A4
(en)
*
|
2019-08-16 |
2023-09-27 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF MYELOID MALIGNANCIES
|
|
JP7712917B2
(ja)
*
|
2019-09-26 |
2025-07-24 |
エフ． ホフマン－ラ ロシュ アーゲー |
抗ｃｓｆ－１ｒ抗体
|
|
US20220348664A1
(en)
*
|
2019-09-26 |
2022-11-03 |
WuXi Biologics Ireland Limited |
A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof
|
|
EP4037699A1
(en)
*
|
2019-09-30 |
2022-08-10 |
SciRhom GmbH |
Protein binders to irhom2 epitopes
|
|
AU2020363372A1
(en)
|
2019-10-07 |
2022-05-19 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
EP4055044A1
(en)
*
|
2019-11-04 |
2022-09-14 |
MedImmune Limited |
Anti il-33 therapeutic agent for treating renal disorders
|
|
JP6761889B1
(ja)
*
|
2019-11-11 |
2020-09-30 |
株式会社Ｇｓｐエンタープライズ |
抗ヒトＣｒｉｐｔｏ−１抗体
|
|
US20220275103A1
(en)
*
|
2019-11-18 |
2022-09-01 |
CentricsBio, Inc. |
Anti-cd300c monoclonal antibody and biomarker thereof for preventing or treating cancer
|
|
WO2021102131A1
(en)
*
|
2019-11-21 |
2021-05-27 |
Brown University |
Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells
|
|
CA3164129A1
(en)
*
|
2019-12-20 |
2021-06-24 |
Amgen Inc. |
Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
|
AU2021207461A1
(en)
*
|
2020-01-13 |
2022-09-01 |
Truebinding, Inc. |
Anti-Gal3 antibodies and methods of use
|
|
EP4093426A1
(en)
|
2020-01-24 |
2022-11-30 |
University of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
PE20221902A1
(es)
*
|
2020-01-24 |
2022-12-21 |
Pfizer |
Anticuerpos anti-e-selectina, composiciones y metodos de uso
|
|
PH12022552038A1
(en)
*
|
2020-02-07 |
2023-11-29 |
Agency Science Tech & Res |
Antigen-binding molecules against alppl2 and/or alpp and uses thereof
|
|
AU2021219671A1
(en)
*
|
2020-02-10 |
2022-07-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-Tmprss2 Antibodies and Antigen-Binding Fragments
|
|
CA3170128A1
(en)
*
|
2020-02-12 |
2021-08-19 |
The Scripps Research Institute |
Long-acting gm-csf and methods of use
|
|
KR102626782B1
(ko)
*
|
2020-02-14 |
2024-01-19 |
주식회사 셀젠텍 |
B세포 성숙화 항원을 표적으로 하는 키메라 항원 수용체 및 이의 용도
|
|
GB202003632D0
(en)
*
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
|
KR102831970B1
(ko)
|
2020-04-02 |
2025-07-11 |
리제너론 파아마슈티컬스, 인크. |
항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
|
|
KR102485892B1
(ko)
*
|
2020-04-09 |
2023-01-09 |
주식회사 에이프릴바이오 |
고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
|
|
BR112022021604A2
(pt)
*
|
2020-04-28 |
2022-12-06 |
Sola Biosciences Llc |
Composições e métodos para tratamento de proteinopatias associadas à tdp-43
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
US12281166B2
(en)
|
2020-05-26 |
2025-04-22 |
Truebinding, Inc. |
Methods of treating inflammatory diseases by blocking Galectin-3
|
|
MX2022014734A
(es)
*
|
2020-05-26 |
2023-03-15 |
Regeneron Pharma |
Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab.
|
|
CN116323665A
(zh)
*
|
2020-05-29 |
2023-06-23 |
23和我公司 |
抗cd200r1抗体及其使用方法
|
|
CN116390941A
(zh)
*
|
2020-07-16 |
2023-07-04 |
南京传奇生物科技有限公司 |
多特异性嵌合抗原受体及其用途
|
|
KR20230038774A
(ko)
|
2020-07-17 |
2023-03-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
호중성 피부병의 치료를 위한 항-il-36r 항체
|
|
TW202212354A
(zh)
*
|
2020-08-03 |
2022-04-01 |
美商健生生物科技公司 |
用於病毒治療劑中之多向生物運輸的材料及方法
|
|
AU2021328262B2
(en)
*
|
2020-08-18 |
2025-06-26 |
Omeros Corporation |
Monoclonal antibodies, compositions and methods for detecting complement factor D
|
|
WO2022056197A1
(en)
*
|
2020-09-11 |
2022-03-17 |
Janssen Biotech, Inc. |
Immune targeting molecules and uses thereof
|
|
PE20231573A1
(es)
*
|
2020-09-18 |
2023-10-04 |
Ichnos Sciences SA |
Anticuerpos biespecificos cd47-cd38
|
|
JP2023543152A
(ja)
*
|
2020-09-18 |
2023-10-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用
|
|
US11795228B2
(en)
*
|
2020-09-30 |
2023-10-24 |
Dren Bio, Inc. |
Anti-CD94 antibodies and methods of use thereof
|
|
US20240018231A1
(en)
*
|
2020-10-30 |
2024-01-18 |
Rush University Medical Center |
Intranasal immunotherapt for the treatment of alzheimer's disease
|
|
CN117285630A
(zh)
*
|
2020-11-09 |
2023-12-26 |
江苏中新医药有限公司 |
抗cd73单克隆抗体及其在制备肿瘤药物中的应用
|
|
CN114470189B
(zh)
*
|
2020-11-12 |
2024-01-16 |
达石药业(广东)有限公司 |
Ngf抗体在cipn性疼痛中的应用
|
|
CA3204702A1
(en)
*
|
2020-12-17 |
2022-06-23 |
F. Hoffmann-La Roche Ag |
Anti-hla-g antibodies and use thereof
|
|
KR20230121096A
(ko)
*
|
2020-12-18 |
2023-08-17 |
에이씨 이뮨 에스에이 |
항체 전달
|
|
WO2022133239A1
(en)
*
|
2020-12-18 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Immunoglobulin proteins that bind to npr1 agonists
|
|
JP2024505390A
(ja)
*
|
2021-01-08 |
2024-02-06 |
ブリストル－マイヤーズ スクイブ カンパニー |
第ｘｉａ因子阻害剤としての抗体および抗原結合ペプチド、およびその使用
|
|
JP7662804B2
(ja)
*
|
2021-03-04 |
2025-04-15 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
汎発性膿疱性乾癬を処置する方法
|
|
WO2022192403A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
JP2024509274A
(ja)
*
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
EP4406592A3
(en)
*
|
2021-03-18 |
2024-10-30 |
MedImmune Limited |
Therapeutic binding molecules
|
|
EP4314070A1
(en)
*
|
2021-03-24 |
2024-02-07 |
Janssen Biotech, Inc. |
Trispecific antibody targeting cd79b, cd20, and cd3
|
|
PE20241732A1
(es)
*
|
2021-03-31 |
2024-08-19 |
Merus Nv |
Dominios de union a pd-1 novedosos
|
|
CN117177994A
(zh)
*
|
2021-03-31 |
2023-12-05 |
美勒斯公司 |
包含新颖pd-1结合域之多特异性结合部分
|
|
CN115260312B
(zh)
*
|
2021-04-30 |
2025-02-14 |
保诺科技（北京）有限公司 |
结合ox40的抗体或抗原结合片段
|
|
US12201857B2
(en)
*
|
2021-06-22 |
2025-01-21 |
Twist Bioscience Corporation |
Methods and compositions relating to covid antibody epitopes
|
|
WO2022270611A1
(ja)
*
|
2021-06-25 |
2022-12-29 |
中外製薬株式会社 |
抗ｃｔｌａ－４抗体
|
|
US12448451B2
(en)
*
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
CN119838007A
(zh)
*
|
2021-06-25 |
2025-04-18 |
中外制药株式会社 |
抗ctla-4抗体的用途
|
|
MX2024000563A
(es)
*
|
2021-07-14 |
2024-04-10 |
Regeneron Pharma |
Anticuerpos y fragmentos de union al antigeno anti-glicoproteína de la espícula de sars-cov-2.
|
|
US11542340B1
(en)
*
|
2021-10-29 |
2023-01-03 |
Biodesix, Inc. |
Antibodies targeting pulmonary nodule specific biomarkers and uses thereof
|
|
KR20250114330A
(ko)
|
2022-11-30 |
2025-07-29 |
인테그럴 몰큘러 인코포레이티드 |
클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식
|
|
KR20250135225A
(ko)
*
|
2023-01-20 |
2025-09-12 |
맵웰 테라퓨틱스 인크. |
항-아밀로이드 β 프로토피브릴/올리고머 항체 및 이의 용도
|
|
WO2024194686A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2025257181A1
(en)
*
|
2024-06-11 |
2025-12-18 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
|